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Re-engineering Drug Discovery and Development
Abstract
The rate of new drug approvals in the US has remained essentially constant since 1950, while the costs of drug
development have soared. Many commentators question the sustainability of the current model of drug
development, in which large pharmaceutical companies incur markedly escalating costs to deliver the same
number of products to market. This Issue Brief summarizes the problem, describes ongoing governmental
efforts to influence the process, and suggests changes in regulatory science and translational medicine that
may promote more successful development of safe and effective therapeutics.
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Editor’s note: The rate of new drug approvals in the US has remained essentially 
constant since 1950, while the costs of drug development have soared.  Many 
commentators question the sustainability of the current model of drug development, 
in which large pharmaceutical companies incur markedly escalating costs to deliver 
the same number of products to market. This Issue Brief summarizes the problem, 
describes ongoing governmental efforts to influence the process, and suggests changes 
in regulatory science and translational medicine that may promote more successful 
development of safe and effective therapeutics.  
Despite enormous investments in drug discovery and development, the number of new 
molecular entities (NMEs) annually approved by the Food and Drug Administration 
(FDA) has hovered around 20-25 for the past 60 years. The rate-limiting step occurs at 
drug development, not drug target discovery. New molecular and genomic technologies 
have produced far more potential drug targets than can be pursued through the 
current development process.  Targets, and the chemistry needed to probe them, can 
be selected more rationally than ever—yet more and more candidate drugs are proving 
expensive failures.
•	 In	the	present	system,	large,	vertically	integrated	pharmaceutical	companies	retain 
in-house expertise at each phase of drug discovery and development. They protect 
their property interests through patents on molecules, most of which never become 
approved drugs.    
•	 According	to	pharmaceutical	industry	data,	a	new	drug	can	take	10-15	years	to 
develop and bring to market. For every 5,000-10,000 compounds that enter the 
research and development (R&D) pipeline, only one receives approval. Although 
substantial variation exists in estimating drug development costs, industry analysts 
estimate that companies spend $1 billion to $4 billion in R&D for every new drug 
brought to market. 
•	 Increasing	public	and	political	pressure	to	lower	prescription	drug	prices	may	
signal lower returns on a company’s R&D investment. In response, pharmaceutical 
companies have shifted their focus to opportunities that promise only the broadest 
markets or the most favorable pricing, such as those for cancer treatment. Companies 
have also pursued a strategy of mergers, but there is no evidence to suggest that these 
mergers have fostered innovation or accelerated the delivery of new drugs. 
Current model of drug 
development is unsustainable
Drug development passes through several stages, including:  [1] the identification of 
drug targets—typically through an understanding of the biological pathways of health 
and disease; [2] medicinal chemistry, in which molecules are structured to attack such 
targets; [3] “drugability” in which those molecules are modified so that their absorption, 
distribution, metabolism, and elimination are consistent with their use in humans; 
[4] proof of concept (POC) studies in cells, animal, or human models; and [5] clinical 
development, including Phase I-IV trials required by the FDA. 
•	 In	the	traditional	model	of	drug	development,	the	pharmaceutical	company	
has expertise in all of these phases, with much more limited roles for academia 
and biotechnology companies. As illustrated below, the traditional approach is 
slowly shifting to a modular, collaborative one that capitalizes on the strengths of 
government, academia, industry, and non-profit organizations. Depending on the 
project, expertise can be drawn from any sector, with risk distributed among the 
various stakeholders. 
Toward a more modular, 
disaggregated model of drug 
development
•	 Examples	of	this	approach	exist	in	the	not-for-profit	sector,	including	Medicines	for	
Malaria Venture (MMV), TB Alliance, and Institute for OneWorld Health. These 
product development partnerships (PDPs) have taken on R&D for neglected diseases 
where there is little commercial incentive to develop drugs. Although the details 
vary, they usually operate as virtual R&D organizations, drawing on the expertise 
of a group to identify targets and partnering with a network of research institutions 
and companies to outsource activities, using philanthropic resources and in-kind 
contributions from partners. One analysis found that PDPs introduced nine new 
products for TB, malaria, meningitis, and leishmaniasis in 10 years, compared to 
14 new drugs developed for neglected diseases in the previous 25 years.  
Vertical Disintegration
PHARMA
Project 1 Project 2 Project 3
BIOTECH
ACADEMIA
Target
ID
Drug-
ability
PK
Modeling
POC
Target
ID
Drug-
ability
POC
cells Target
ID POC
POC
models
Phase I
Phase III
Phase IV
Marketing
Phase 
II
PK
Modeling
Target
ID
Drug-
ability
POC
cells
POC
models
Phase I
Phase III
Phase IV
Marketing
Phase 
II
PK
Modeling
Target
ID
Drug-
ability
POC
cells
POC
models
Phase I
Phase III
Phase IV
Marketing
Phase 
II
PK
Modeling
Target
ID
Drug-
ability
POC
cells
POC
models
Phase I
Phase III
Phase IV
Marketing
Phase 
II
POLICY IMPLICATIONS The current drug development process is inefficient and unsustainable. Development, 
approval, and monitoring of drugs will rely increasingly on coordination and collaboration 
among industry, academia, and regulatory bodies, as well as on the sharing of information 
in an open and timely manner.  Several initiatives at the NIH and FDA are underway to 
facilitate the shift to a more modular, collaborative model. 
•	 In	August	2011,	the	FDA	released	a	strategic	plan	for	advancing	regulatory	science.	
The plan calls for the FDA to develop new tools, standards, disease models and science-
based pathways to improve the speed, efficiency, predictability, capacity and quality of 
the entire process, from drug development to evaluation to manufacturing. However, 
budget restrictions have eliminated the FDA’s plans to devote an additional $25 million 
to regulatory science. The initiative is now being supported through existing funds, 
which will likely limit its scope.
•	 The	proposed	National	Center	for	Advancing	Translational	Science	(NCATS)	has	run	
into political and budgetary obstacles. As of this writing, it remains unfunded. The 
original proposal called for NCATS to be supported through transfer of funds from 
existing institutes (primarily the National Center for Research Resources, which would 
be eliminated) and the $100 million authorized (though not appropriated) for the 
Continued on back.
Re-engineering the process 
calls for changes in 
educational, regulatory, 
and informatics infrastructure
The transition to a more modular approach will require linked initiatives among 
academia, the pharmaceutical industry, the National Institutes of Health (NIH), 
and the FDA.
•	 It	will	have	to	address	the	serious	deficit	in	scientists	with	expertise	in	translation	
medicine and therapeutics (TMAT) and regulatory science. A working group 
recently recommended that the NIH develop clear career tracks for translational 
medicine, with programs that include training in clinical pharmacology, systems 
biology, biomarker development, and cross-sector training with the FDA and the 
pharmaceutical industry. The Wellcome Trust has funded four centers of excellence 
in Great Britain; each center has an industrial partner that contributes expertise to 
the teaching program and an environment where trainees can be exposed to drug 
development in the setting of a for-profit company. 
•	 Increasingly,	policymakers	are	recognizing	that	encouraging	and	rewarding	
innovation requires changes in regulations, and that improving regulations requires 
science of its own—regulatory science. Regulatory reforms could protect and 
expand the precompetitive space, fostering an earlier, more thorough understanding 
of drug action. The FDA might create a “safe haven” for systems physiology and 
pharmacology, akin to its approach to pharmacogenomics. The FDA could also 
consider incentives for earlier detection of adverse events and unintended therapeutic 
effects by using a more graded or gradual approach to introduction to and withdrawal 
from the marketplace. 
•	 The	new	approach	requires	an	informatics	infrastructure	that	permits	global,	secure, 
and compliant sharing of data across academic, industry, and regulatory sectors.  
Some of this activity has begun. For example, the NIH Chemical Genomics Center 
(NCGC) recently created the NCGC Pharmaceutical Collection, a complete list of 
all approved molecular entities as a freely available electronic resource and a physical 
collection of small molecules available for further screening for new uses in rare and 
neglected diseases.
•	 Recognizing	the	need	to	re-engineer	the	translational	process,	the	NIH	has	proposed	
a new National Center for Advancing Translational Science, which would aggregate 
existing resources pertinent to translational medicine. The proposed center would 
house the 60 existing Clinical and Translational Science Awards (CTSAs) and their 
educational infrastructure, as well as a collaboration between the NIH and FDA, and 
foster academia-industry interactions. 
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Cures Acceleration Network, a drug development grant program included in last year’s 
health reform legislation. More efforts are needed to communicate how, in this new 
drug development model, NCATS will complement, rather than compete with, public 
and private sector translational activities.
•	 The	FDA	Science	Board	recently	recommended	funding	FDA	Centers	of	Excellence	
within academia.  Such centers would provide FDA experts in regulatory science with 
a critical mass of complementary expertise and a neutral testing ground on which to 
explore drug action independent of the sponsor while remaining mindful of proprietary 
interests—a kind of Jet Propulsion Laboratory for the FDA. A call for one such 
center—limited to within 50 miles of the FDA campus—has recently been made.
•	 A	key	issue	in	applying	the	non-profit	modular	model	to	the	for-profit	world	of	
drug development is the role of intellectual property and patents.  A new framework 
of intellectual property should be considered—one that rewards successful R&D 
investment while encouraging early collaboration and data sharing. Perhaps the 
financial rewards of a patent should be postponed until a drug is a profitable success—
and a formal mechanism found to distribute rewards among all those who helped make 
it happen.
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